Gilead Announces Promotion of Katie Watson to Executive Vice President, Human Resources

FOSTER CITY, Calif.--(BUSINESS WIRE)--Feb. 1, 2016-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced the promotion of Katie Watson to Executive Vice President, Human Resources.

Ms. Watson joined Gilead in February 2003 and since that time has taken on increasing levels of responsibility and management within the HR organization. Ms. Watson was appointed Vice President of Employee Development and Rewards in 2012 and was promoted to Senior Vice President, Human Resources in 2013. Before joining Gilead, she was a manager of compensation for Applera Corporation, led the HR consulting practice for TriNet and worked as an HR business partner for DE Shaw & Co. Ms. Watson holds a degree in Psychology from the University of California at San Diego and a master's in Organizational Psychology from Columbia University.

"Katie and her team continue to play an invaluable role during a period of significant hiring and growth at Gilead," said John C. Martin, PhD, Chairman and Chief Executive Officer, Gilead Sciences. "During Katie's tenure, Gilead has grown from approximately 1,000 to more than 8,000 dedicated employees. Her understanding of the complexities of Gilead's business has allowed her to contribute significantly to building an organization that today reaches millions of patients around the world."

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California.

For more information on Gilead Sciences, please visit the company's website at, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

View source version on

Source: Gilead Sciences, Inc.

Gilead Sciences, Inc.
Patrick O'Brien, 650-522-1936
Amy Flood, 650-522-5643

- See more at:

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

Janssen is tapping little-known and privately held Hemera Biosciences for a new gene therapy aimed at reversing a severe disease.

Harvard scientists showed that a three-gene cocktail, by epigenetic reprogramming, could reverse the aging clock in mice retina nerve cells.

Merck is clearly still buzzing about its two-year Dragonfly Therapeutics pact, as it has snapped up a cancer program.